137 related articles for article (PubMed ID: 38385995)
21. The Current Landscape for
Desai A; Cuellar S
J Adv Pract Oncol; 2022 Jul; 13(5):539-544. PubMed ID: 35910499
[TBL] [Abstract][Full Text] [Related]
22. Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report.
Chen Z; Zhu F; Li C; Li J; Cheng B; Xiong S; Zhong R; Liang W; He J
Ann Transl Med; 2021 Mar; 9(5):424. PubMed ID: 33842645
[TBL] [Abstract][Full Text] [Related]
23. Savolitinib for non-small cell lung cancer.
Zaborowska-Szmi M; Szmit S; Krzakowski M; Kowalski DM
Drugs Today (Barc); 2023 Jan; 59(1):17-36. PubMed ID: 36811415
[TBL] [Abstract][Full Text] [Related]
24. Combinatorial therapy is a safe and durable treatment option in
Jang C; Sabari J
Transl Lung Cancer Res; 2023 Dec; 12(12):2558-2564. PubMed ID: 38205199
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
26. Consensus Recommendations for the Diagnosis, Biomarker Testing, and Clinical Management of Advanced or Metastatic Non-small Cell Lung Cancer With Mesenchymal-Epithelial Transition Exon 14 Skipping Mutations in the Middle East, Africa, and Russia.
Mahrous M; Omar Jebriel A; Allehebi A; Shafik A; El Karak F; Venturini F; Alhusaini H; Meergans M; Ali Nahit Sendur M; Ouda M; Al-Nassar M; Kilickap S; Al Turki S; Al-Fayea T; Abdel Kader Y
Cureus; 2023 Jul; 15(7):e41992. PubMed ID: 37492039
[TBL] [Abstract][Full Text] [Related]
27. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
[TBL] [Abstract][Full Text] [Related]
28. Pathological complete response in an advance stage IIIB non-small cell lung cancer secondary to neoadjuvant osimertinib targeted therapy: A case report and review of literature.
Soo CI; Ong DB; Chin KK; Sia LC; Munusamy V; Ibrahim NH; Loh TC; Tan JL; Poh ME; Wong CK; Pang YK; Liam CK
Respirol Case Rep; 2023 Jul; 11(7):e01181. PubMed ID: 37350988
[TBL] [Abstract][Full Text] [Related]
29. Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer.
Bai Q; Shi X; Zhou X; Liang Z; Lu S; Wu Y
Ther Adv Med Oncol; 2024; 16():17588359231216096. PubMed ID: 38188466
[TBL] [Abstract][Full Text] [Related]
30. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of stage IIIB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD-1 inhibitor camrelizumab: A case report.
Zhu SG; Li HB; Dai TX; Li H; Wang GY
World J Clin Cases; 2022 Sep; 10(27):9743-9749. PubMed ID: 36186195
[TBL] [Abstract][Full Text] [Related]
32. Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas.
Li Y; Gao L; Ma D; Qiu T; Li W; Li W; Guo L; Xing P; Liu B; Deng L; Fu J; Li J; Yu Y; Ying J
Lung Cancer; 2018 Aug; 122():113-119. PubMed ID: 30032818
[TBL] [Abstract][Full Text] [Related]
33. Complete pathological response and negative postoperative ctDNA were not predictive of discontinuation of adjuvant crizotinib therapy in a patient with locally advanced MET ex14 skipping mutation-positive non-small cell lung cancer: a case report.
Wang J; Yao W; Wang W; Fan M; Huang K; Liu Z; Zhu D
Front Oncol; 2023; 13():1164543. PubMed ID: 37554169
[TBL] [Abstract][Full Text] [Related]
34. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
35. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
Mazieres J; Vioix H; Pfeiffer BM; Campden RI; Chen Z; Heeg B; Cortot AB
Clin Lung Cancer; 2023 Sep; 24(6):483-497. PubMed ID: 37451931
[TBL] [Abstract][Full Text] [Related]
36. First-line tepotinib for a very elderly patient with metastatic NSCLC harboring
Inno A; Bogina G; Settanni G; Salgarello M; Foti G; Pomari C; Picece V; Gori S
Drug Target Insights; 2023; 17():110-113. PubMed ID: 37840886
[TBL] [Abstract][Full Text] [Related]
37. Survival outcomes and prognostic factors of lung cancer patients with the
Gow CH; Hsieh MS; Chen YL; Liu YN; Wu SG; Shih JY
Front Oncol; 2023; 13():1113696. PubMed ID: 36969059
[TBL] [Abstract][Full Text] [Related]
38. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
Cortot A; Le X; Smit E; Viteri S; Kato T; Sakai H; Park K; Camidge DR; Berghoff K; Vlassak S; Paik PK
Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
[TBL] [Abstract][Full Text] [Related]
39. Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib.
Zhang L; Wang Y; Lin L; Yu Y; Lu S
Ther Adv Med Oncol; 2023; 15():17588359231216089. PubMed ID: 38145112
[TBL] [Abstract][Full Text] [Related]
40. Successful tepotinib treatment of adenocarcinoma with MET exon 14 skipping and discordant results between Oncomine Dx target test and ArcherMET: A case report.
Onodera Y; Sekine A; Hagiwara E; Yamada S; Ikeda S; Tabata E; Kitamura H; Baba T; Komatsu S; Okudela K; Ogura T
Mol Clin Oncol; 2023 Jun; 18(6):49. PubMed ID: 37228358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
